Quince Therapeutics (QNCX) Gains from Investment Securities (2023 - 2026)

Quince Therapeutics' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$64.3 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities changed N/A year-over-year to -$64.3 million; the TTM figure through Mar 2026 stood at -$44.7 million (down 9558.75% YoY), while the FY2025 annual figure was $21.5 million, changed N/A from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$64.3 million, down from $17.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $17.0 million in Q4 2025, with the low at -$64.3 million in Q1 2026.
• The 4-year median for Gains from Investment Securities is $1.8 million (2023), against an average of -$5.1 million.
• Peak annual rise in Gains from Investment Securities reached 178.27% in 2025, while the deepest fall reached 76.04% in 2025.
• Quince Therapeutics' Gains from Investment Securities stood at $1.6 million in 2023, then plunged by 270.03% to -$2.7 million in 2024, then surged by 732.8% to $17.0 million in 2025, then tumbled by 478.9% to -$64.3 million in 2026.
• Business Quant data shows QNCX's Gains from Investment Securities at -$64.3 million in Q1 2026, $17.0 million in Q4 2025, and $2.1 million in Q3 2025.